248 related articles for article (PubMed ID: 34118951)
1. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Wu B; Yuan Y; Liu J; Shang H; Dong J; Liang X; Wang D; Chen Y; Wang C; Zhou Y; Jing H; Cheng W
J Nanobiotechnology; 2021 Jun; 19(1):177. PubMed ID: 34118951
[TBL] [Abstract][Full Text] [Related]
2. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
3. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
4. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
George J; Afek A; Keren P; Herz I; Goldberg I; Haklai R; Kloog Y; Keren G
Circulation; 2002 May; 105(20):2416-22. PubMed ID: 12021230
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma.
Yang H; Jing H; Han X; Tan H; Cheng W
Drug Des Devel Ther; 2021; 15():531-542. PubMed ID: 33603343
[TBL] [Abstract][Full Text] [Related]
6. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
7. Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.
Beiner ME; Niv H; Haklai R; Elad-Sfadia G; Kloog Y; Ben-Baruch G
Int J Gynecol Cancer; 2006; 16 Suppl 1():200-6. PubMed ID: 16515591
[TBL] [Abstract][Full Text] [Related]
8. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
10. Sinoporphyrin sodium based sonodynamic therapy induces anti-tumor effects in hepatocellular carcinoma and activates p53/caspase 3 axis.
Li E; Sun Y; Lv G; Li Y; Zhang Z; Hu Z; Cao W
Int J Biochem Cell Biol; 2019 Aug; 113():104-114. PubMed ID: 30660690
[TBL] [Abstract][Full Text] [Related]
11. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC.
Chen Y; Shang H; Wang C; Zeng J; Zhang S; Wu B; Cheng W
Int J Nanomedicine; 2022; 17():105-123. PubMed ID: 35027829
[TBL] [Abstract][Full Text] [Related]
12. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
[TBL] [Abstract][Full Text] [Related]
13. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Borbath I; Stärkel P
Acta Gastroenterol Belg; 2011 Mar; 74(1):34-44. PubMed ID: 21563652
[TBL] [Abstract][Full Text] [Related]
15. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
17. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
18. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Wu L; Pang Y; Qin G; Xi G; Wu S; Wang X; Chen T
PLoS One; 2017; 12(2):e0171840. PubMed ID: 28182780
[TBL] [Abstract][Full Text] [Related]
19. Sonosensitizer Nanoplatforms Augmented Sonodynamic Therapy-Sensitizing Shikonin-Induced Necroptosis Against Hepatocellular Carcinoma.
Tian H; Shang H; Chen Y; Wu B; Wang C; Wang X; Cheng W
Int J Nanomedicine; 2023; 18():7079-7092. PubMed ID: 38050474
[TBL] [Abstract][Full Text] [Related]
20. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
